Abbott And J&J Products Go Head-To-Head In Anti-TNF And HIV Markets
Executive Summary
Abbott will rely on efficacy data for its TNF inhibitor Humira and HIV therapy Kaletra as each product takes on a new competitor from Johnson & Johnson
You may also be interested in...
J&J Aims For Virology Leadership, But Pipeline Covers Traditional Strengths
Johnson & Johnson is positioning itself to become a major player in the virology market through its recently approved protease inhibitor Prezista and the development of two non-nucleoside reverse transcriptase inhibitors
J&J Aims For Virology Leadership, But Pipeline Covers Traditional Strengths
Johnson & Johnson is positioning itself to become a major player in the virology market through its recently approved protease inhibitor Prezista and the development of two non-nucleoside reverse transcriptase inhibitors
J&J Enters HIV Arena With Prezista; Darunavir Is Tenth Protease Inhibitor
The strength of darunavir's bond with protease may provide Johnson & Johnson/Tibotec's Prezista an advantage against other drugs in the class for treatment-experienced HIV patients